In conclusion, it will not take long before PARP inhibitors will be part of regular clinical practice. After a long journey from research hypothesis to clinical application, PARP inhibitors are the first example of a targeted treatment based on the synthetic lethality principle. This journey boosted various aspects of cancer research, such as development of biomarkers and patient selection tools, smart design of clinical trials and extensive research on drug resistance mechanisms, which will need continuation for quite some time to answer the many remaining questions. The development of PARP inhibitors not only extended insights in fundamental knowledge on DDR mechanisms, but also showed the power of bidirectional translational cancer research.
Personalized Medicine. 2015;12(2):139-154. © 2015 Future Medicine Ltd.